DENTSPLY International Inc. Announces Launch Of Oraqix.YORK, Pa. -- DENTSPLY International Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :XRAY) today announced that it has initiated the United States product launch of Oraqix(R) (lidocaine lidocaine /li·do·caine/ (li´do-kan) an anesthetic with sedative, analgesic, and cardiac depressant properties, applied topically in the form of the base or hydrochloride salt as a local anesthetic; also used in the latter form as a and prilocaine periodontal periodontal /peri·odon·tal/ (per?e-o-don´t'l) 1. pertaining to the periodontal ligament or periodontium. 2. near or around a tooth. per·i·o·don·tal adj. 1. gel) 2.5%/2.5%, local anesthetic local anesthetic n. An agent that, when applied directly to mucous membranes or when injected about the nerves, produces loss of sensation by inhibiting nerve excitation or conduction. for periodontal administration, a new needle free dental anesthetic. Gary Kunkle, Vice Chairman and Chief Executive Officer, commented that "The Company is very pleased to announce the launch of Oraqix(R) in the United States. This needle free dental anesthetic is indicated for adults who require local anesthesia Anesthesia, Local Definition Local or regional anesthesia involves the injection or application of an anesthetic drug to a specific area of the body, as opposed to the entire body and brain as occurs during general anesthesia. for root planing and/or scaling procedures. Oraqix(R) will allow periodontal patients to enjoy the benefits of local anesthesia during scaling and/or root planning procedures without requiring an injection." The Company also announced that it has entered into an exclusive distribution agreement with OraPharma, Inc., a division of Johnson & Johnson, for the sales of Oraqix(R) in the United States. Kunkle added, "OraPharma, a well-established dental pharmaceutical company, is well positioned to help accelerate Oraqix'(R) acceptance in the dental market. OraPharma has over 100 sales professionals calling on periodontists and a targeted group of periodontal focused general practitioners." Kunkle concluded, "Planning for our launch of Oraqix(R) in international markets continues. We anticipate launching the product in Sweden later in the fourth quarter, and expanding throughout Europe in 2005 as additional country approvals are granted." DENTSPLY designs, develops, manufactures and markets a broad range of products for the dental market. The Company believes that it is the world's leading manufacturer and distributor of dental prosthetics, precious metal dental alloys, dental ceramics, endodontic Endodontic Pertaining to the inside structures of the tooth, including the dental pulp and tooth root, and the periapical tissue surrounding the root. Mentioned in: Root Canal Treatment endodontic instruments and materials, prophylaxis paste, dental sealants, ultrasonic scalers, dental injectible anesthetics Anesthetics Drugs or methodologies used to make a body area free of sensation or pain. Mentioned in: Appendectomy and crown and bridge materials; the leading United States manufacturer and distributor of dental handpieces, dental x-ray film holders, film mounts and bone substitute/grafting materials; and a leading worldwide manufacturer or distributor of impression materials, orthodontic orthodontic (ôr´th  dän´tik),adj appliances, dental cutting instruments and dental implants. The Company distributes its dental products in over 120 countries under some of the most well established brand names in the industry. DENTSPLY is committed to the development of innovative, high quality, cost-effective new products for the dental market. This press release contains forward-looking statements regarding future events or the future financial performance of the Company. Actual events or results may differ materially from those in the projections or other forward-looking statements set forth herein as a result of certain risk factors. These risk factors include without limitation; the ability to continue to generate sufficient cash flow to pay down debt as planned, the continued strength of dental markets, the timing, success and market reception for our new product introductions, and changes in the general economic environment that could affect our business. For an additional description of risk factors, please refer the Company's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. filed with the Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion